Inovio Pharmaceuticals Holds Annual Stockholders Meeting

An announcement from Inovio Pharmaceuticals ( (INO) ) is now available.

On May 20, 2025, Inovio Pharmaceuticals held its Annual Meeting of Stockholders where four proposals were considered. The proposals included the election of eight directors, the ratification of Ernst & Young LLP as the independent auditor, approval of executive compensation, and amendment of the 2023 Omnibus Incentive Plan. Each proposal received varying levels of support from the stockholders, reflecting the company’s ongoing governance and strategic planning efforts.

The most recent analyst rating on (INO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Inovio Pharmaceuticals stock, see the INO Stock Forecast page.

Spark’s Take on INO Stock

According to Spark, TipRanks’ AI Analyst, INO is a Neutral.

Inovio Pharmaceuticals’ stock score reflects significant financial struggles, including persistent losses and negative cash flows, which weigh heavily on its overall assessment. While technical indicators show some neutral momentum and there are positive developments in their product pipeline, the financial health concerns and valuation challenges are prominent risks. Recent earnings call highlights show progress but also underline ongoing financial difficulties.

To see Spark’s full report on INO stock, click here.

More about Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The company primarily targets infectious diseases and cancer, aiming to provide innovative solutions in these areas.

Average Trading Volume: 633,785

Technical Sentiment Signal: Sell

Current Market Cap: $78.12M

For detailed information about INO stock, go to TipRanks’ Stock Analysis page.